Brief: Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation Of Anti-Cancer Immune Cells With MDNA11 Treatment
22/12/2021 13:19
Dec 22 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES PRELIMINARY CLINICAL DATA SHOWING
PREFERENTIAL STIMULATION OF ANTI-CANCER IMMUNE CELLS WITH MDNA11
TREATMENT IN THE PHASE 1/2 ABILITY STUDY
* MEDICENNA THERAPEUTICS CORP - MDNA11-INDUCED INCREASES IN
CD8+ T
AND NK CELLS COMPARE FAVORABLY TO COMPETING IL-2 VARIANTS IN
CLINIC
* MEDICENNA - NO DOSE LIMITING TOXICITY, OR ANY EVIDENCE OF
CYTOKINE RELEASE SYNDROME, NOR ANY EVIDENCE OF VASCULAR LEAK
SYNDROME HAS BEEN OBSERVED
Source text for Eikon: ID:nGNXGkg9y
Further company coverage: MDNA.TO
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results